Lenacapavir Campaign
A campaign to expand access to a critical HIV prevention medication
On October 2, 2024, Gilead Sciences announced that it had signed voluntary licensing agreements with six generics manufacturers for its twice-yearly injectable PrEP product lenacapavir. However, Gilead excluded several countries from its licensing territory and included restrictive agreement terms that will leave many without access.
Statement from Civil Society to Gilead Sciences for Equitable Access to Lenacapavir (May 7, 2025) HTML | PDF (Spanish) | PDF (English)
Letters from Civil Society to the Presidents of 22 Latin American Countries Emphasizing the Need to Ensure Access to Lenacapavir (December 18, 2024) HTML (GHP Corp)